late night

Most Read

FDA Pushes Back Against Opioid Epidemic

The FDA requested Endo Pharmacueticals remove the opioid Opana ER from the market because of its highly addictive qualities, and the serious communicable diseases that are often spread when people inject the drug via needle-sharing. In its statement, the FDA recognized the national opioid epidemic as a basis for its decision and committed to continue a risk versus benefit analysis with respect to opioid approval.

[DIGEST: CNN 1, 2, Philly, NBC, FDA, Opana]

For the first time, the Food and Drug Administration (FDA) is seeking to ban a previously approved opioid due to its addictive qualities. In this decision, the FDA specifically recognized the public health risk of the opioid epidemic and committed to making other similar evaluations with other drugs.

Keep reading... Show less